Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Onderzoek naar gelijktijdige toediening van een onderzoekend, levend verzwakt vaccin tegen respiratoir syncytieel virus bij zuigelingen en peuters (CORAL)

15 september 2026 bijgewerkt door: Sanofi Pasteur, a Sanofi Company

Fase III, gerandomiseerde, enkelblinde, placebogecontroleerde, multicentrische studie om de niet-interferentie van gelijktijdige toediening van routinematige kindervaccins op de antilichaamrespons van een onderzoekend levend verzwakt respiratoir syncytieel virus (RSV)-vaccin bij gezonde zuigelingen te evalueren en Peuters (KORAAL)

This study is a Phase III, randomized, single-blind, placebo-controlled, multi-center study to be conducted in healthy infants and toddlers which will be enrolled at approximately 6 months of age (Cohort 1) and approximately 12 months of age (Cohort 2). The primary objective of the study will be to assess non-inferiority of the RSV infant and toddler (RSVt) vaccine antibody response when administered concomitantly with routine pediatric vaccines at 6 months of age (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine [Vaxelis® or Pentacel® and Recombivax HB®] Prevnar 20®, and RotaTeq®), and 12 months of age (M-M-R II, VARIVAX, and Prevnar 20 or per local country recommendations) compared to when administered non-concomitantly.

Studie Overzicht

Gedetailleerde beschrijving

The study duration is approximately 9 months for each participant.

  • Cohort 1: Visits at 6, 7, and 8 and 9 months of age for both groups with visit at 10 months of age for Group 2 only
  • Cohort 2: Visits at 12, 13, 14 and 15 months of age for both groups with visit at 16 months of age for Group 4 only
  • Routine pediatric vaccines (authorized auxiliary medicinal products (AxMP) will be administered at 6 months in Cohort 1 and 12 months of age in Cohort 2, as per Advisory Committee on Immunization Practice (ACIP) or local country recommendations.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

2226

Fase

  • Fase 3

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

      • Mexico City, Mexico, 06760
        • Investigational Site Number : 4840004
    • Mexico City
      • Mexico City, Mexico City, Mexico, 04530
        • Investigational Site Number : 4840001
    • Morelos
      • Temixco, Morelos, Mexico, 62587
        • Investigational Site Number : 4840002
      • Caguas, Puerto Rico, 00725
        • Investigational Site Number : 6300001
      • Ponce, Puerto Rico, 00716
        • Investigational Site Number : 6300003
      • Trujillo Alto, Puerto Rico, 00976
        • Investigational Site Number : 6300004
    • Alabama
      • Birmingham, Alabama, Verenigde Staten, 35205
        • Alabama Clinical Therapeutics - Birmingham - St. Vincent's Drive- Site Number : 8400007
      • Grand Bay, Alabama, Verenigde Staten, 36541
        • South Alabama Medical Clinic- Site Number : 8400065
      • Mobile, Alabama, Verenigde Staten, 36608
        • MedPharmics - Mobile - Dauphin Street- Site Number : 8400017
    • Arkansas
      • Fayetteville, Arkansas, Verenigde Staten, 72703
        • Northwest Arkansas Pediatric Clinic- Site Number : 8400002
    • California
      • Bell Gardens, California, Verenigde Staten, 90201
        • Alliance Research Institute - Bell Gardens - Garfield Avenue- Site Number : 8400040
      • Huntington Park, California, Verenigde Staten, 90255
        • Matrix Clinical Research - Huntington Park- Site Number : 8400018
      • La Mesa, California, Verenigde Staten, 91942
        • Paradigm Clinical Research Centers- Site Number : 8400059
      • Los Angeles, California, Verenigde Staten, 90057
        • Matrix Clinical Research - Los Angeles- Site Number : 8400008
      • Oakland, California, Verenigde Staten, 94611
        • Kaiser Permanente - Oakland Medical Center- Site Number : 8400047
      • Palo Alto, California, Verenigde Staten, 94304
        • Stanford University Medical Center CTRU - 800 Welch Road- Site Number : 8400070
      • Roseville, California, Verenigde Staten, 95661
        • Kaiser Permanente - Sierra Gardens- Site Number : 8400063
      • Sacramento, California, Verenigde Staten, 95815
        • Kaiser Permanente - Point West Medical Offices- Site Number : 8400064
      • San Jose, California, Verenigde Staten, 95119
        • Kaiser Permanente - San Jose Medical Center- Site Number : 8400060
      • Santa Clara, California, Verenigde Staten, 95051
        • Kaiser Permanente - Santa Clara Medical Center- Site Number : 8400061
      • Sherman Oaks, California, Verenigde Staten, 91356-4173
        • Integrated Clinical Research LLC- Site Number : 8400036
      • Walnut Creek, California, Verenigde Staten, 94596
        • Kaiser Permanente - Walnut Creek Medical Center- Site Number : 8400062
    • District of Columbia
      • Washington D.C., District of Columbia, Verenigde Staten, 20016
        • Velocity Clinical Research - Washington DC- Site Number : 8400050
    • Florida
      • Doral, Florida, Verenigde Staten, 33166
        • Prohealth Research Center- Site Number : 8400068
      • Hollywood, Florida, Verenigde Staten, 33021
        • The Medici Medical Research- Site Number : 8400055
      • Miami, Florida, Verenigde Staten, 33126
        • Dade Research Center- Site Number : 8400014
      • Miami Lakes, Florida, Verenigde Staten, 33014
        • Riveldi Biomedical Research and Associates - Miami Lakes- Site Number : 8400015
      • Pensacola, Florida, Verenigde Staten, 32501
        • SEC Clinical Research - Pensacola- Site Number : 8400034
      • Tampa, Florida, Verenigde Staten, 33613
        • PAS Research- Site Number : 8400005
    • Idaho
      • Idaho Falls, Idaho, Verenigde Staten, 83404
        • Leavitt Women's Healthcare- Site Number : 8400009
    • Iowa
      • Sioux City, Iowa, Verenigde Staten, 51106
        • Velocity Clinical Research - Sioux City- Site Number : 8400054
    • Kansas
      • El Dorado, Kansas, Verenigde Staten, 67042
        • Alliance for Multispeciality Research - El Dorado- Site Number : 8400019
    • Kentucky
      • Lexington, Kentucky, Verenigde Staten, 40536
        • University of Kentucky Chandler Medical Center- Site Number : 8400051
    • Louisiana
      • New Orleans, Louisiana, Verenigde Staten, 70119
        • Velocity Clinical Research - New Orleans- Site Number : 8400058
      • New Orleans, Louisiana, Verenigde Staten, 70125
        • Research Works INC- Site Number : 8400044
    • Mississippi
      • Gulfport, Mississippi, Verenigde Staten, 39503
        • Velocity Clinical Research - Gulfport- Site Number : 8400011
    • Missouri
      • Springfield, Missouri, Verenigde Staten, 65802
        • QPS Bio-Kinetic Clinical Applications- Site Number : 8400046
    • Montana
      • Great Falls, Montana, Verenigde Staten, 59405
        • Boeson Research - Great Falls- Site Number : 8400041
      • Missoula, Montana, Verenigde Staten, 59804
        • Boeson Research - Missoula- Site Number : 8400006
    • Nebraska
      • Grand Island, Nebraska, Verenigde Staten, 68803
        • Velocity Clinical Research - Grand Island- Site Number : 8400016
      • Lincoln, Nebraska, Verenigde Staten, 68516
        • Midwest Childrens Health Research Institute- Site Number : 8400038
      • Omaha, Nebraska, Verenigde Staten, 68134
        • Velocity Clinical Research - Omaha- Site Number : 8400001
    • Nevada
      • Henderson, Nevada, Verenigde Staten, 89014
        • PAS Research - Henderson- Site Number : 8400049
    • New York
      • Garden City, New York, Verenigde Staten, 11530
        • NYU Langone Cardiothoracic Surgery Associates - Garden City- Site Number : 8400048
      • Liverpool, New York, Verenigde Staten, 13088
        • Summerwood Pediatrics- Site Number : 8400021
      • Syracuse, New York, Verenigde Staten, 13210
        • SUNY Upstate Medical University - Syracuse- Site Number : 8400029
    • Ohio
      • Dayton, Ohio, Verenigde Staten, 45414
        • Ohio Pediatrics - Dayton- Site Number : 8400033
      • Dayton, Ohio, Verenigde Staten, 45409
        • Dayton Clinical Research- Site Number : 8400030
      • South Euclid, Ohio, Verenigde Staten, 44121
        • Senders Pediatrics- Site Number : 8400022
    • Oregon
      • Gresham, Oregon, Verenigde Staten, 97030
        • Cyn3rgy Research- Site Number : 8400053
    • Pennsylvania
      • Erie, Pennsylvania, Verenigde Staten, 16506
        • Square-1 Clinical Research- Site Number : 8400031
      • Pittsburgh, Pennsylvania, Verenigde Staten, 15227
        • Pas Research - Pittsburgh- Site Number : 8400043
    • South Carolina
      • Charleston, South Carolina, Verenigde Staten, 29407
        • Neighbors Pediatrics- Site Number : 8400072
      • Greenville, South Carolina, Verenigde Staten, 29607
        • Tribe Clinical Research - Greenville - Verdae Boulevard- Site Number : 8400012
    • Texas
      • Corpus Christi, Texas, Verenigde Staten, 78413
        • South Texas Clinical Research- Site Number : 8400004
      • Dallas, Texas, Verenigde Staten, 75230
        • Javara - Privia Medical Group North Texas - Dallas- Site Number : 8400003
      • Edinburg, Texas, Verenigde Staten, 78539
        • PAS Research - Children's Care Clinic- Site Number : 8400035
      • Fort Worth, Texas, Verenigde Staten, 76104
        • Helios Clinical Research - Fort Worth - 8th Avenue- Site Number : 8400020
      • Houston, Texas, Verenigde Staten, 77008
        • Ventavia Research Group - Houston - North Loop West- Site Number : 8400010
      • Houston, Texas, Verenigde Staten, 77065
        • DM Clinical Research - Houston - Jones Road- Site Number : 8400052
      • Houston, Texas, Verenigde Staten, 77070
        • Mercury Clinical Research - Houston - Savoy Drive- Site Number : 8400045
      • Houston, Texas, Verenigde Staten, 77090
        • Houston Clinical Research Associates- Site Number : 8400013
      • Houston, Texas, Verenigde Staten, 77030
        • The University of Texas Health Science Center- Site Number : 8400037
      • Houston, Texas, Verenigde Staten, 77071
        • La Providence Pediatrics & Family Clinics- Site Number : 8400039
      • League City, Texas, Verenigde Staten, 77555
        • University of Texas Medical Branch at Galveston- Site Number : 8400057
      • League City, Texas, Verenigde Staten, 77573
        • Maximos Ob/Gyn- Site Number : 8400024
      • Plano, Texas, Verenigde Staten, 75093
        • Research Your Health- Site Number : 8400066
      • Richmond, Texas, Verenigde Staten, 77469
        • Pediatric Center - Richmond- Site Number : 8400032
      • Tomball, Texas, Verenigde Staten, 77375
        • North Houston Internal Medicine & Pediatric Clinic- Site Number : 8400025
    • Utah
      • Orem, Utah, Verenigde Staten, 84057
        • Utah Valley Pediatrics - Orem- Site Number : 8400067
      • Pleasant View, Utah, Verenigde Staten, 84404
        • Ogden Clinic - Mountain View - CCT Research- Site Number : 8400056
      • Roy, Utah, Verenigde Staten, 84067
        • Wee Care Pediatrics - Roy- Site Number : 8400071

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

6 maanden tot 1 jaar (Kind)

Accepteert gezonde vrijwilligers

Ja

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Aged 6 months for Cohort 1 and 12 months for Cohort 2 on the day of inclusion ("6 months" means from the day of the 6-month birthday to the day before the 7-month birthday and "12 months" means from the day of the 12-month birthday to the day before the 13-month birthday)
  • Participants who are healthy as determined by medical evaluation including medical history and physical examination
  • For Cohort 1: Infant received doses of vaccines containing hepatitis B, diphtheria, tetanus, pertussis, Haemophilus influenzae type B (Hib), and inactivated poliovirus vaccine (IPV) antigens, with Advisory Committee on Immunization Practice (ACIP) recommended vaccines. The last dose(s) of these vaccines must be at least 28 days before the first study visit
  • Infant received the recommended doses of a recommended pneumococcal conjugate vaccine (as per local schedule) at least 28 days before the first study visit.

Exclusion Criteria:

  • Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
  • Known previous infection with diphtheria, tetanus, Hib, measles, mumps, rubella, rotavirus, pneumococcus, polio, hepatitis B virus
  • Known systemic hypersensitivity to any of the study intervention components, or history of a life-threatening reaction to the study intervention used in the study or to a product containing any of the same substances
  • Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion
  • History of medically diagnosed wheezing
  • Any acute febrile illness in the past 48 hours that according to investigator judgment is significant enough to interfere with successful inoculation on the day of vaccination. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.
  • Probable or confirmed ongoing case of viral respiratory infection (including COVID 19, influenza, rhinovirus, etc.) at the time of enrollment. A prospective participant should not be included in the study until the respiratory infection has resolved.
  • Member of a household that contains an immunocompromised individual, including, but not limited to:
  • A person living with human immunodeficiency virus (HIV)
  • A person who has received chemotherapy within the 12 months prior to study enrollment
  • A person who has received (within the past 6 months) or is receiving (at the time of enrollment) immunosuppressant agents
  • A person living with a solid organ or bone marrow transplant
  • Potential close contact with other immunocompromised individual within 30 days after each vaccination as per investigator's discretion
  • History of definitive contraindications to any of the concomitant vaccines that will be administered as part of the study protocol
  • Participant's biological mother with previous receipt or planned administration of an investigational RSV vaccine during pregnancy and/or breastfeeding
  • Receipt of any vaccine in the 4 weeks preceding RSVt vaccine administration or planned receipt of any vaccine outside of study protocol in the 4 weeks following RSVt vaccine administration, except for influenza and/or COVID-19 vaccination, which may be received at least 1 week before or 1 week after RSVt vaccine administration
  • Previous receipt of an investigational RSV vaccine or receiving any anti RSV product (such as ribavirin or RSV immune globulin) at the time of enrollment
  • Receipt of immune globulins, blood or blood-derived products in the past 3 months
  • Receipt of intranasal and intra-ocular medications within 3 days prior to study enrollment
  • Previous receipt of an RSV monoclonal antibody within 6 months prior to the first study vaccine administration or planned receipt for duration of the study
  • For Cohort 1: Prior receipt of routine 6-month pediatric vaccine doses (as per local schedule)
  • For Cohort 2: Prior receipt of routine 12-month pediatric vaccine doses (as per local schedule)
  • Participation at the time of study enrollment (or in the 6 weeks preceding the first study intervention administration) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure

Note: The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Preventie
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Verdrievoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Cohort 1: Group 1- (RSVt vaccine concomitantly at 6 months)

Participants will be administered RSVt vaccine concomitantly with routine pediatric vaccines, 2 doses, at age 6 months. Vaccines administered at age 6 months: RSVt Vaxelis or Pentacel and Recombivax HB, Prevnar 20, and RotaTeq. Placebo will be administered non-concomitantly at 7 months of age

Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

Andere namen:
  • 534

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Andere namen:
  • Vaxelis®

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Andere namen:
  • Pentacel®

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Andere namen:
  • RECOMBIVAX HB® of een alternatief monovalent hepatitis B-vaccin

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Andere namen:
  • PREVNAR 20®

Pharmaceutical form:Oral solution-Route of administration:Oral

Andere namen:
  • RotaTeq®

Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

Experimenteel: Cohort 1: Group 2- (RSVt vaccine non-concomitantly at 7 months)

Participants will be administered RSVt vaccine non-concomitantly with routine pediatric vaccines, 2 doses, at age 7 months. Vaccines administered at age 6 months: Vaxelis or Pentacel and Recombivax HB, Prevnar 20, and RotaTeq. Placebo will be administered concomitantly at 6 months of age

Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

Andere namen:
  • 534

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Andere namen:
  • Vaxelis®

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Andere namen:
  • Pentacel®

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Andere namen:
  • RECOMBIVAX HB® of een alternatief monovalent hepatitis B-vaccin

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Andere namen:
  • PREVNAR 20®

Pharmaceutical form:Oral solution-Route of administration:Oral

Andere namen:
  • RotaTeq®

Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

Experimenteel: Cohort 2: Group 3- (RSVt vaccine concomitantly at 12 months)

Participants will be administered RSVt vaccine concomitantly with routine pediatric vaccines, 2 doses, at age 12 months. Vaccines administered at age 6 months: M-M-R II, VARIVAX, and Prevnar 20. Placebo will be administered non-concomitantly at 13 months of age

Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

Andere namen:
  • 534

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Andere namen:
  • PREVNAR 20®

Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

Pharmaceutical form:Lyophilized live virus for reconstitution -Route of administration:Subcutaneous or Intramuscular

Andere namen:
  • M-M-R® II

Pharmaceutical form:Suspension for injection-Route of administration:Subcutaneous or Intramuscular

Andere namen:
  • VARIVAX®
Experimenteel: Cohort 2: Group 4- (RSVt vaccine non-concomitantly at 13 months)

Participants will be administered RSVt vaccine non-concomitantly with routine pediatric vaccines, 2 doses, at age 13 months. Vaccines administered at age 6 months: M-M-R II, VARIVAX, and Prevnar 20. Placebo will be administered concomitantly at 12 months of age

Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

Andere namen:
  • 534

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Andere namen:
  • PREVNAR 20®

Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

Pharmaceutical form:Lyophilized live virus for reconstitution -Route of administration:Subcutaneous or Intramuscular

Andere namen:
  • M-M-R® II

Pharmaceutical form:Suspension for injection-Route of administration:Subcutaneous or Intramuscular

Andere namen:
  • VARIVAX®

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
RSV A serum neutralizing antibody titers at 28 days post dose 2 (D85) Groups 1 and 3
Tijdsspanne: Day 85

Antibody titers at Day 85

Day 85
RSV B serum neutralizing antibody titers at 28 days post dose 2 (D85) Groups 1 and 3
Tijdsspanne: Day 85

Antibody titers at Day 85

Day 85
RSV A serum neutralizing antibody titers at Day 113 Groups 2 and 4
Tijdsspanne: Day 113

Antibody titers at Day 113

Day 113
RSV B serum neutralizing antibody titers at Day 113 Groups 2 and 4
Tijdsspanne: Day 113

Antibody titers at Day 113

Day 113

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Anti- hepatitis B surface antigen (HBsAg) Immunoglobulin g (IgG) antibody (A)b concentrations ≥ 10 milli international units per milliliter (mIU/mL) Cohort 1
Tijdsspanne: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Anti- polyribosylribitol phosphate (PRP) Ab concentrations ≥ 0.15 micrograms per milliliter (µg/mL) Cohort 1
Tijdsspanne: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Anti-poliovirus types (1, 2, and 3) Ab titers ≥ 1:8 Cohort 1
Tijdsspanne: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Anti-pertussis Ab concentrations pertussis toxin, filamentous hemagglutinin , pertactin, fimbriae (PT, FHA, PRN, FIM) Cohort 1
Tijdsspanne: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Anti-diphtheria Ab concentrations ≥ 0.1 IU/mL Cohort 1
Tijdsspanne: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Anti-tetanus Ab concentrations ≥ 0.1 IU/mL Cohort 1
Tijdsspanne: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Anti-pneumococcal Ab concentrations measured by electrochemiluminescence (ECL) for serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F Cohort 1
Tijdsspanne: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Anti-measles Ab concentrations ≥ 255 mIU/mL Cohort 2
Tijdsspanne: 28 days after the 12 month routine vaccinations

Antibody titers 28 days after the 12 month routine vaccinations

28 days after the 12 month routine vaccinations
Anti-mumps Ab concentrations ≥ 10 antibody units (AbU/mL) Cohort 2
Tijdsspanne: 28 days after the 12 month routine vaccinations

Antibody titers 28 days after the 12 month routine vaccinations

28 days after the 12 month routine vaccinations
Anti-rubella Ab concentrations ≥ 10 IU/mL Cohort 2
Tijdsspanne: 28 days after the 12 month routine vaccinations

Antibody titers 28 days after the 12 month routine vaccinations

28 days after the 12 month routine vaccinations
Anti-varicella Ab concentrations ≥ 5 glycoprotein enzyme-linked immunosorbent assay (gpELISA) units/mL Cohort 2
Tijdsspanne: 28 days after the 12 month routine vaccinations

Antibody 28 days after the 12 month routine vaccinations

28 days after the 12 month routine vaccinations
Anti-pneumococcal Ab concentrations measured by ECL Cohort 2
Tijdsspanne: 28 days after the 12 month routine vaccinations

Antibody titers 28 days after the 12 month routine vaccinations

28 days after the 12 month routine vaccinations
Descriptive: Anti-PRP Ab concentrations (µg/mL) Cohort 1
Tijdsspanne: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Descriptive: Anti-diphtheria Ab concentrations (IU/mL) Cohort 1
Tijdsspanne: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Descriptive: Anti-diphtheria Ab concentrations ≥ 0.01 IU/mL Cohort 1
Tijdsspanne: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Descriptive: Anti-tetanus Ab concentrations (IU/mL) Cohort 1
Tijdsspanne: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Descriptive: Anti-tetanus Ab concentrations ≥ 0.01 IU/mL Cohort 1
Tijdsspanne: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Descriptive: Anti-HBsAg Ab concentrations (mIU/mL) Cohort 1
Tijdsspanne: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Descriptive: Anti-HBsAg Ab concentrations ≥ 100 mIU/mL Cohort 1
Tijdsspanne: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Descriptive: Anti-poliovirus types (1, 2, and 3) Ab titers Cohort 1
Tijdsspanne: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Descriptive: Anti-measles Ab concentrations (mIU/mL) Cohort 2
Tijdsspanne: 28 days after the 12 month routine vaccinations

Antibody titers 28 days after the 12 month routine vaccinations

28 days after the 12 month routine vaccinations
Descriptive: Anti-mumps Ab concentrations (AbU/mL) Cohort 2
Tijdsspanne: 28 days after the 12 month routine vaccinations

Antibody titers 28 days after the 12 month routine vaccinations

28 days after the 12 month routine vaccinations
Descriptive: Anti-rubella Ab concentrations (IU/mL) Cohort 2
Tijdsspanne: 28 days after the 12 month routine vaccinations

Antibody titers 28 days after the 12 month routine vaccinations

28 days after the 12 month routine vaccinations
Descriptive: Anti-varicella Ab concentrations (gpELISA units/mL)
Tijdsspanne: 28 days after the 12 month routine vaccinations

Antibody titers 28 days after the 12 month routine vaccinations

28 days after the 12 month routine vaccinations
RSV A serum neutralizing antibody titers by baseline serostatus at Day 1 Cohort 1 and Cohort 2
Tijdsspanne: Day 1

Antibody titers at Day 1

Day 1
RSV B serum neutralizing antibody titers by baseline serostatus at Day 1 Cohort 1 and Cohort 2
Tijdsspanne: Day 1

Antibody titers at Day 1

Day 1
RSV A serum neutralizing antibody titers by baseline serostatus 28 days post-dose 2 1 Cohort 1 and Cohort 2
Tijdsspanne: 28 days post-dose 2

Antibody titers 28 days post-dose 2

28 days post-dose 2
RSV B serum neutralizing antibody titers by baseline serostatus 28 days post-dose 2 Cohort 1 and Cohort 2
Tijdsspanne: 28 days post-dose 2

Antibody titers 28 days post-dose 2

28 days post-dose 2
Presence of solicited administration site reactions within 21 days after each investigational medicinal product (IMP) administration Cohort 1 and Cohort 2
Tijdsspanne: 21 days after each IMP administration

Number of participants experiencing solicited administration site reactions

21 days after each IMP administration
Presence of solicited systemic reactions within 21 days after each IMP administration Cohort 1 and Cohort 2
Tijdsspanne: 21 days after each IMP administration

Number of participants experiencing solicited systemic site reactions

21 days after each IMP administration
Presence of unsolicited systemic adverse events (AEs) reported in the 30 minutes after each study intervention administration Cohort 1 and Cohort 2
Tijdsspanne: Within 30 minutes after each study intervention administration

Number of participants experiencing unsolicited systemic adverse events

Within 30 minutes after each study intervention administration
Presence of unsolicited AEs within 28 days after each study intervention administration Cohort 1 and Cohort 2
Tijdsspanne: Within 28 days after each study intervention administration

Number of participants experiencing unsolicited AEs

Within 28 days after each study intervention administration
Presence of medically attended adverse events (MAAEs) throughout the study Cohort 1 and Cohort 2
Tijdsspanne: Throughout the study, approximately 9 months

Number of participants experiencing MAAEs

Throughout the study, approximately 9 months
Presence of serious adverse events (SAEs) throughout the study Cohort 1 and Cohort 2
Tijdsspanne: Throughout the study, approximately 9 months

Number of participants experiencing SAEs

Throughout the study, approximately 9 months
Presence of adverse events of special interest (AESIs) throughout the study Cohort 1 and Cohort 2
Tijdsspanne: Throughout the study, approximately 9 months

Number of participants experiencing AESIs

Throughout the study, approximately 9 months

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

13 mei 2024

Primaire voltooiing (Werkelijk)

18 september 2025

Studie voltooiing (Werkelijk)

18 september 2025

Studieregistratiedata

Eerst ingediend

29 april 2024

Eerst ingediend dat voldeed aan de QC-criteria

29 april 2024

Eerst geplaatst (Werkelijk)

3 mei 2024

Updates van studierecords

Laatste update geplaatst (Werkelijk)

5 oktober 2026

Laatste update ingediend die voldeed aan QC-criteria

15 september 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren